Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ATI-2138

Other · developed by Aclaris Therapeutics

Phase 2 Most advanced trial (none active)
ACRS Developer
1 Registered trials

What is ATI-2138?

ATI-2138 is an investigational drug studied in Atopic Dermatitis.

At a glance

Drug type
Other
Therapy area
Dermatology
Developer
Aclaris Therapeutics, Inc. (ACRS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
JKD3CP7SWF

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06585202 Phase 2 Atopic Dermatitis Completed ACRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atopic Dermatitis

More from Aclaris Therapeutics

A-101 FDA approved ATI 502 Phase 2 ATI-045 Phase 2 ATI-1777 Phase 2 ATI-50002 Phase 2 ATI-501 Phase 2 Zunsemetinib Phase 2

Follow ACRS, the company behind ATI-2138

See ACRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACRS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.